457 Plasminogen activating inhibitor-1 could be a key factor for the induction of angiogenesis in cutaneous angiosarcomas

Plasminogen activating inhibitor-1 (PAI-1) is classically known as an angiogenesis promoting factor that associated with poor clinical outcomes in various cancers, including skin cancer such cutaneous melanomas. Cutaneous angiosarcoma (CAS) a vascular tumor histologically characterized by detachment of endothelial cell-derived cells. Since CAS expresses multiple angiogenic growth factors and has increased expressions receptor tyrosine kinase transcripts VEGFR1/2/3, angiogenesis-promoting are potential drug targets CAS. In this study, at first, the expression PAI-1 was examined 31 cases CAS, next, immunomodulatory effects on human cell line, ISO-HAS-B, were evaluated. We found that, factors, expressed 93.5% (29 31) even intensely 64.5% (20 cases. vitro analysis revealed mRNA IL-23p19, VEGF-C, CXCL5, CCL20 ISO-HAS-B. IL-23p19 production from ISO-HAS-B validated ELISA. Moreover, immunohistochemical staining for showed 61.3% cases, VEGF-C 41% addition, producing cells IL-17 detected lesional Notably, serum levels CXCL5 tended to correlate disease activity each case treated eribulin mesylate. The results present study suggest promotes progression inhibitors might be